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Abstract
The aim of this study was to map the microbiota distribution along the gut and
establish whether colon/faecal samples from diabetic rats adequately reflect the
diabetic alterations in the microbiome. Streptozotocin-treated rats were used to
model type 1 diabetes mellitus (T1D). Segments of the duodenum, ileum and colon
were dissected, and the microbiome of the lumen material was analysed by using
next-generation DNA sequencing, from phylum to genus level. The intestinal
luminal contents were compared between diabetic, insulin-treated diabetic and
healthy control rats. No significant differences in bacterial composition were found
in the luminal contents from the duodenum of the experimental animal groups,
whereas distinct patterns were seen in the ileum and colon, depending on the
history of the luminal samples. Ileal samples from diabetic rats exhibited particularly
striking alterations, while the richness and diversity obscured some of the
modifications in the colon. Characteristic rearrangements in microbiome
composition and diversity were detected after insulin treatment, though the normal
gut flora was not restored. The Proteobacteria displayed more pronounced shifts
than those of the predominant phyla (Firmicutes and Bacteroidetes) in the rat model
of T1D. Diabetes and insulin replacement affect the composition of the gut
microbiota in different, gut region-specific manners. The luminal samples from the
ileum appear more suitable for diagnostic purposes than the colon/faeces. The
Proteobacteria should be at the focus of diagnosis and potential therapy. Klebsiella
are recommended as biomarkers of T1D.
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Introduction
Type 1 diabetes (T1D) is an autoimmune disease that results from the T cell-
mediated destruction of insulin-producing beta cells [1]. Recent studies suggest
that there might be an inflammation-triggering effect of the intestinal microbiota
in the development of autoimmune diabetes [2–5]. The link between the gut
microbiota and the development of autoimmune diabetes can be explained by the
shared lymphocyte-homing receptors in the gut and inflamed pancreas [6]. T1D is
frequently associated with a variety of gastrointestinal (GI) motility abnormalities
in which selective nitrergic myenteric neuropathy has been well documented both
in humans [7–9] and in rodent models [10–12]. Nevertheless, diabetes-related
enteric neuropathy as an immune-mediated disease has received less attention.
We earlier demonstrated [10–11] that myenteric neurones and microvessels
adjacent to the myenteric ganglia are direct targets of diabetes, and the rate and
extent of their damage depend strictly on the intestinal segment in which the
particular neurones or capillaries are located. Moreover, their responsiveness to
insulin replacement is also gut region-dependent. These observations indicated a
diabetes-related pathological microenvironment, allowing neurones to survive in
a strictly intestinal segment-specific way, even under appropriate glycaemic
control. Several studies have indicated that, in addition to being targets of
inflammation, the peptidergic enteric neurones modulate the immune cell
function and can therefore stimulate pro-inflammatory cytokine production and
result in neurodegeneration [13–15]. These data suggest that the pathogenic
cascade which leads to the development of autoimmune diabetes through secreted
lymphokines might also result in altered neuro-immune interactions and provoke
myenteric neuropathy. Of the potential environmental triggers implicated in the
development of diabetes-related myenteric neuropathy, the intestinal microbiome
is regarded as primary candidate.
The microbiome of the gut has been extensively studied, particularly in
humans, during the past few years, including major metagenomic projects in the
USA [16–19] and Europe [20–22]. A major limitation of these mega efforts is the
fact that the overwhelming majority of the samples used to study microbial events
in the gut were taken from stools, i.e. material from the very end of food
processing. The underlying assumption that all microbes thriving in the gut are
equally represented in the stools is at best only partially correct [23–27]. The
relative simplicity and non-invasive nature of this sampling method remain the
main justifications of this approach.
In consequence of the difficulties in sample collection, much less is known
about the composition of the microbiota in the duodenum, jejunum and ileum in
healthy or various disease states. Although the available data indicate a gut region-
specific composition of the microbiota associated with health and GI disorders,
this situation is frequently disregarded [23–28].
Our study was inspired by the findings that myenteric neurones and
microvessels in different intestinal segments display various susceptibilities to
diabetic damage and also exhibit different responses to insulin treatment. In an
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attempt to search for a causal relationship between the prevalence of bacteria in
the specific parts of the GI tract and the region-specific pathological
microenvironments, we investigated the spatial distribution of the microbes along
the gut of diabetic and insulin-treated diabetic rats relative to healthy controls.
Materials and Methods
Animal model
Adult male Wistar rats (Crl:WI BR; Toxi-Coop Zrt.) weighing 290–300 g, kept on
standard laboratory chow (BioplanKft.) and with free access to drinking water,
were used throughout the experiments. The rats were divided randomly into three
groups: animals with STZ-induced diabetes (n58), animals with insulin-treated
diabetes (n58), and sex- and age-matched controls (n56). Hyperglycaemia was
induced by a single intraperitoneal injection of STZ (Sigma, USA) [10]. Forty-
eight hours later, the nonfasting blood glucose concentration was determined in
blood obtained from the cut tip of the tail by the glucose oxidase method, using a
portable blood glucose monitoring device (D-Cont Personal, 77 Elektronika Kft,
Hungary). The animals were considered diabetic if the non-fasting blood glucose
concentration was .18 mM [10–11]. From this time on one group of
hyperglycaemic rats received a subcutaneous injection of insulin (Humulin M3;
Eli Lilly Nederland) each morning (4 U) and afternoon (2 U). The non-fasting
blood glucose concentration and weight of each animal were measured weekly. In
all procedures involving experimental animals, the principles of laboratory animal
care (NIH Publication No. 85-23, revised 1985) were strictly followed, and all the
experiments were approved in advance by the Local Ethics Committee for Animal
Research Studies at the University of Szeged.
Tissue handling and collection of intestinal contents
Ten weeks after the onset of diabetes, the animals were killed by cervical
dislocation under chloral hydrate anaesthesia (375 mg/kg i.p). The gut segments
of the rats in the control, STZ-induced diabetes and insulin-treated diabetes
groups were dissected and rinsed in sterile distilled water (Milli-Q). Samples were
taken from the duodenum (10-cm-long samples from distal to the pylorus), the
ileum (10-cm-long samples from proximal to the ileo-caecal junction), and the
entire colon and processed for metagenomic studies. For the collection of
intestinal contents, the dissected gut segments were washed thoroughly twice with
a strong jet of sterile distilled water (2610 ml, Milli-Q). This combined solution
was shaken in sterile Falcon tubes and divided into 2 ml aliquots, which were and
frozen at 280 C˚ until DNA extraction.
DNA isolation for metagenomic studies
The lumen contents of each gut segments (362 ml) were used to prepare the total
community DNA. The cells were lysed in three different lysis solutions (Table 1);
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enzymatic (lysozyme), chemical (cetyltrimethylammonium bromide, CTAB) and
physical (heat or mechanical) cell wall disintegration methods were employed.
The lysis conditions were optimized for each GI segment. Samples from the
duodenum and ileum were incubated at 37 C˚ for 1 h to complete cell disruption
in each lysis solution (A, B and C in Table 1); the more concentrated colon
samples were treated with bead disintegration. After lysis, samples from the
duodenum and ileum were mixed with 125 ml (duodenum) or 200 ml (ileum)
Qiagen QIAamp Stool AL (Qiagen, 51504) buffer and 25 ml proteinase K (Panreac
Applichem GmbH, A3830), and were further incubated at 56 C˚ for 1 h. The DNA
samples were next centrifuged (12,000 rpm, 2 min) and the DNA from the
supernatant was precipitated with 400 ml chilled ethanol. In the following steps,
the manufacturers’ instructions were followed as given in the Qiagen QIAamp
DNA Stool DNA (duodenum and ileum) and Zymo Research Fecal DNA
miniprep (Zymo Research Europe) (colon) kits, respectively. Finally, the DNA
isolated from the various GI segments with each lysis method was combined. The
DNA preparations from the intestinal segments of 3 rats for each condition were
isolated separately and parallel samples were pooled for sequencing.
The quantity of DNA was determined in a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies) and Qubit 2.0 Fluorometer (Life
Technologies). DNA purity was tested by agarose gel electrophoresis and by
Agilent 2200 Tape Station (Agilent Technologies).
Next-generation DNA sequencing and data handling
The sample preparation for total metagenome sequencing of the pooled samples
was carried out following the recommendations of Ion Torrent PGM sequencing
platform (Life Technologies). Sequencing was performed using Ion Torrent PGM
316 chips [29]. The reads were analysed and quality values were determined for
Table 1. Cell lysis conditions applied to obtain maximum DNA for the next-generation sequencing of the microbial community in the various segments of the
GI tract.
GI tract
segment Lysozyme1[ml]
10% CTAB2
[ml]
genomic CTAB
lysis buffer3 [ml]
Qiagen
buffer4 [ml]
Zymo
buffer5 [ml]
Heat/Bead
disruption
Duodenum A – 50 – – 150 Heat
B 50 – – 150 – Heat
C 50 – 150 – – Heat
Ileum A - 50 – – 250 Heat
B 50 – – 250 – Heat
C 50 – 250 – – Heat
Colon A - 100 – 100 550 Bead
B 250 100 – 100 300 Bead
C 250 – 300 200 – Bead
1100 mg/ml (Applycehm). 2Cetyltrimethylammonium bromide (w/v). 31 M Tris-HCl 100 ml, 500 mM EDTA 50 ml, 5 M NaCl 300 ml, 10% CTAB, 20% SDS,
pH5829. 4ASL buffer from Qiagen QIAamp DNA Stool miniprep kit (Qiagen, 51504). 5From Zymo Research Fecal DNA kit (Zymo Research, D6010).
doi:10.1371/journal.pone.0110440.t001
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each nucleotide. The 100–200 nucleotide long individual sequences were further
analysed by using the MG-RAST software package, which is a modified version of
RAST (Rapid Annotations based on Subsystem Technology). The MG-RAST
server initially runs a quality control test. If the data appear reliable, the system
automatically screens for sequences of potential protein encoding regions via a
BLASTX search against the comprehensive non-redundant database compiled
from various publicly available sequencing centres and other sources. These
databases include several rDNA datasets, e.g. GREENGENES, RDP II and
European 16S RNA, among other information sources. The generated matches to
external databases were used to compute the derived data. Details of the statistical
calculations were published [29].
Results
Weight and glycaemic characteristics of experimental animals
Ten weeks after the onset of diabetes, the diabetic rats were characterized by a
reduced body weight and an increased blood glucose concentration as compared
with the age- and sex-matched controls. The insulin-treated diabetic rats did not
differ significantly from the control animals in weight or blood glucose
concentration (Table 2).
The composition of the microbiome along the gut
Two sets of metagenomic data were evaluated throughout the present study. The
distributions at phylum, class and order levels (Figures 1–3) included all DNA
reads comprising the eukaryotic sequences and unassigned ones. The latter
indicated the number of sequences that could not be assigned to any known
prokaryotic genome uploaded onto publicly available databases. In this way, we
intended to present both the variations due to unrelated or unidentifiable data
and the distribution of abundances among the bacterial taxa. The most important
results are indicated at a genus level for the control, the diabetic and insulin-
treated ileum in figure 2 and for diabetic colon in Figure 3.
The microbiome of the duodenum
In line with the low abundance of the microbiological community in this region,
the overwhelming majority of the DNA sequences from the duodenal samples
related to rodents (93–96%, Figure 1). The few prokaryotes comprised mostly
members of the phylum Firmicutes and class Bacilli. When the eukaryotic and
unidentified sequences were removed from the database, 31–49% of the total
reads were due to the order Lactobacillales, comprising almost entirely members of
the genus Lactobacillus (data not shown). The richness and distribution of
prokaryotes did not differ markedly in the diabetic and insulin-treated diabetic
rats relative to the healthy controls (Figure 1).
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The microbiome of the ileum
The microbiome of the control ileum
Only 3% of the DNA sequences originated from eukaryotic cells in this segment.
The ileum was populated by Bacteria, but representatives of Archaea (0.01%) also
occurred (Figure 2A). The majority of the domain Bacteria belonged in the phyla
Table 2. Weight and glycaemic characteristics of the three experimental groups of rats.
Rat group Body weight (g) ¡ SEM Blood glucose concentration (mM) ¡ SEM
initial final initial final
Controls (n56) 292.7¡1.8 417.0¡13.9*** 6.3¡0.2 5.4¡0.1
Diabetics (n58) 297.8¡5.8 347.5¡19.3* 5.9¡0.3 30.8¡1.6***
Insulin-treated diabetics (n58) 299.3¡5.2 397.3¡9.6 *** 5.9¡0.3 4.0¡0.6
Initial vs. final: *p,0.05; ***p,0.001.
doi:10.1371/journal.pone.0110440.t002
Figure 1. Compositions of the control, diabetic and insulin-treated diabetic bacterial microbiomes in the duodenum at domain, phylum and class
levels. Only the predominant order Lactobacillales is indicated. The abbreviated and colour-coded taxa are indicated on the right side in systematic
sequence. ‘‘Other sequences’’ are probably those of viruses not covered in the databases used. The majority of the identified DNA sequences related to the
Eukaryota, indicating the overall low abundance of microbes. Among the Bacteria the Lactobacillales predominated. No significant differences were
observed between the control and the diabetic and insulin-treated diabetic samples.
doi:10.1371/journal.pone.0110440.g001
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Firmicutes (57%) and Proteobacteria (about 30%). The majority of the Firmicutes
were identified in the class Bacilli, order Lactobacillales (55%) and genus
Lactobacillus (54%). The genera Escherichia (19%) and Shigella (11%) pre-
dominated in the Proteobacteria.
The microbiome of the diabetic ileum
Striking differences were observed in the composition of the microbial
community of the ileal lumen between the diabetic rats and the controls (
Figures 2A and 2B). Among the Firmicutes (50%), the genus Lactobacillus
predominated (48%) and Streptococcus (2%) was also detected, the distribution
strongly resembling that in the control ileum. The Actinobacteria (not observed in
the controls) appeared with representatives of the order Corynebacterium (2%).
The total ratio of Proteobacteria was not changed greatly (42% as compared with
33% in the control ileum), but a massive invasion by the genus Klebsiella (31%)
Figure 2. Compositions of the control, diabetic and insulin-treated diabetic microbiomes in the ileum at domain, phylum, class and order levels.
The orders Enterobacteriales (2B), Clostridiales and Bacteroidetes (2C), displaying the most striking differences, are shown in higher resolution. The
abbreviated and colour-coded taxa are indicated on the right side in systematic sequence. ‘‘Other sequences’’ are probably those of viruses not covered in
the databases used. Taxa with very low (,1%) abundances are indicated to two decimal places. A striking invasion of the genus Klebsiella was apparent in
diabetes. It is noteworthy that the insulin treatment eliminated the Klebsiella invasion, but did not restore the ‘‘healthy’’ microbiome, and the representation of
the classes Clostridia and Bacteroidia increased massively.
doi:10.1371/journal.pone.0110440.g002
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led to its predominance in the bacterial sequences in the diabetic ileum (
Figure 2B).
The microbiome of the insulin-treated diabetic ileum
Insulin treatment resulted in a major reorganization of the microbial community
of the ileum (Figure 2C). The ratio of Firmicutes did not change (48%), but the
Bacteroidetes (scarce in the controls) made up 16% of the reads, accounting
almost exclusively for the members of the genus Bacteroides (data not shown). The
Actinobacteria were represented twice as strongly as in the diabetic samples (the
order Bifidobacteriales 9% replacing the order Corynebacterium in the diabetic
ileum). At the level of lower taxonomic units, characteristic signs of increasing
microbial diversity and rearrangement of the microbiota were evident. Within the
Firmicutes, the order Clostridiales (hardly detectable in the controls) was enriched
to an astonishing 30% relative abundance. This order consisted essentially of two
genera in equal representation, Clostridium and Peptostreptococcus. Insulin
Figure 3. Compositions of the control, diabetic and insulin- treated diabetic microbiomes in the colon at domain, phylum, class and order levels.
The abbreviated and colour-coded taxa are indicated on the right side in systematic sequence. Two minor classes belonging in the phylum Firmicutes are
marked only with colours. ‘‘Other sequences’’ are probably those of viruses not covered in the databases used. Taxa with very low (,1%) abundances are
indicated to two decimal places. The diversity of the microbial community was increased significantly in the insulin-treated diabetic animals, members of the
order Bacteroidales predominating. The order Enterobacteriales is shown at higher resolution in diabetes (3B). The presence of the Klebsiella in the diabetic
samples was still clearly seen although not as markedly as in the case of the ileum. Insulin promoted the abundance of the order Bifidobacteriales.
doi:10.1371/journal.pone.0110440.g003
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treatment was apparently deleterious for the order Lactobacillales in the class
Bacilli: their number decreased 4-fold relative to the control and the diabetic
ileum. The Proteobacteria, including the genus Klebsiella, the indicative signature
of diabetes, were practically eradicated by insulin from the ileum of the diabetic
rats. Only the order Burkholderiales represented the Proteobacteria, in 2%
abundance. A notably high proportion of the microbial community (20%)
remained unassigned in these samples. Although rationalization of the consider-
able changes in the various taxa as a result of insulin medication requires further
study, it is clear that the microbial community of the ileum was rearranged and
diversified substantially.
The microbiome of the colon
The microbiome of the control colon
The number of Archaea (0.1%) found in the colon was still small relative to the
domain Bacteria, but was 10-fold higher relative to that in the ileum. The phyla
Firmicutes and Bacteroidetes predominated in the colon of the control rats (
Figure 3A). These two phyla each comprised 40% of all the identified sequences,
Proteobacteria (4% representation) and Spirochaetes (2%) were also present. The
other microbial phyla displayed significantly lower relative abundances. At the
genus level, the order Clostridiales consisted primarily of the genera Clostridium
(11%), Eubacteria (6%), Ruminococcus (5%) and Lactobacillus (4%). The most
abundant bacteria in the order Bacteroidales were categorized in the genera
Bacteroides (18%), Prevotella (12%) and Alistipes (5%).
The microbiome of the diabetic colon
The abundances of the major phyla did not differ to a great extent in the colon
samples of the diabetic and the control rats. The phyla Bacteroidetes (38%) and
Firmicutes (37%) accounted for the overwhelming majority, followed by the
Proteobacteria (11%). The Bacteroides (19%), Prevotella (15%) and Alistipes (4%)
(not shown) were the major genera within the Bacteroidetes. The Firmicutes
comprised mostly members of the genera Clostridium (12%), Eubacterium (6%),
Lactobacillus (5%) and Ruminococcus (4%) (not shown). Major differences
between the colon samples of the control and the diabetic rats were therefore
hardly detectable at a genus level in the Bacteroidetes and Firmicutes. In contrast,
the composition of the Proteobacteria differed significantly. Whereas members of
the genera Helicobacter, Wolinella and Desulfovibrio were identified in the colon
samples of the control rats, all of them in ,0.5% abundance, their major
representatives in the colon of the diabetic rats belonged in the genus Klebsiella.
The relative abundance of 6% was significantly less than that observed in the
diabetic ileum, but still noteworthy as compared with the control or insulin-
treated colon communities (Figure 3B).
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The microbiome of the insulin-treated colon
Insulin treatment of the diabetic rats resulted in significant differences in the
colon microbiome, which rather resembled that in the ileum, although the
differences relative to the controls were less pronounced (Figures 2C, 3A and 3C).
The most obvious of the insulin effects on the microbiota was a general escalation
of the diversity of the microbial community. The phyla Bacteroidetes and
Firmicutes still ruled over the microbial landscape, totalling 44% and 30% of the
population, respectively. Among the other phyla, the Actinobacteria were
appreciably represented (8%), followed by the Proteobacteria (6%) and
Spirochaetes (2%). It should be noted that the insulin treatment was accompanied
by fundamental changes within the phylum Proteobacteria: their overall
abundance decreased spectacularly, and the genus Klebsiella was basically
eradicated, being replaced by the genera Desulfovibrio and Bifidobacterium, with a
combined abundance of 4% (not shown).
Discussion
The overwhelming majority of studies published to date on the role of enteric
pathogens in the development of autoimmune diabetes [30–32] were carried out
on faecal samples. Community-level investigations were recently extended to
metagenomic [33], meta-proteomic [34] and metabolomics [35] descriptions of
pathological alterations in the GI microbiome, but all involved faecal samples.
Thus, these data do not necessarily reflect the microbiological events that take
place in the various segments of the GI system under the pathological conditions
leading to T1D and related enteric neuropathies. In order to explore the possible
correlation between the diabetes-related gut region-dependent nitrergic myenteric
neuropathy and the altered mesenteric capillaries [10–11] and the spatially-
restricted distribution of the gut microbiota, we therefore carried out a
metagenomic analysis of the luminal contents of the duodenum, ileum and colon
of rats with STZ-induced diabetes and insulin-treated diabetes in comparison
with control rats.
The proximal part of the GI tract does not harbour a rich microbial
community: around 104–105 cells/g are found there [36]. The predominance of
Lactobacillus strains, which characteristically inhabit the upper gut, [37] was not
markedly different in the duodenal luminal contents of the diabetic and the
insulin-treated diabetic rats. Accordingly, the composition of the duodenal
microbiota did not indicate the development of a pathological enteric
microenvironment. This is in good agreement with our earlier findings that in
STZ-induced diabetes the duodenum was the only gut segment in which a
decrease in the number of nitrergic myenteric neurones was not accompanied by a
decrease in the total number of neurones,10 and the limited diabetes-related
structural alterations in the mesenteric capillaries were completely prevented by
insulin treatment [11].
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In the ileum, where a significant decrease in the total number of myenteric
neurones is accompanied by severe structural damage of the mesenteric capillaries
in rats with STZ-induced diabetes, [10–11] the diabetes is characterized by a
massive Klebsiella invasion. The Klebsiella are among the most common Gram-
negative bacteria that cause severe intestinal inflammation in humans [38–39].
The mucosal inflammation results in a leaky epithelium; this allows the easier
passage of bacteria through the intestinal epithelium, initiating a pathological
cascade disturbing the intestinal immunology, a critical element in the
development of the autoimmune T1D [40–42]. The aberrant microbiota that
develops in the ileum in STZ-induced diabetes and the characteristic upsurge of
the Gram-negative Klebsiella could therefore be directly associated with the
inflammation and the development of the pathological microenvironment,
leading to both autoimmune diabetes and diabetes-related enteric neuropathy. It
is not clear whether the Klebsiella contribute directly to the advance of the disease,
or whether the weakened intestinal barrier facilitates the growth of the Klebsiella,
i.e. whether the Klebsiella are the cause or the consequence of the autoimmune
disease. It is noteworthy that a close relative from the same family, the pathogenic
Escherichia coli, has been identified as the main culprit in various GI tract diseases,
including autoimmune diabetes, in humans [43–48]. We found that insulin
treatment brought about a drastic reorganization of the microbial community in
the luminal content of the ileum. The microbial diversity increased enormously.
The Protobacteria were practically eliminated and the genus Klebsiella, the
indicative signature of diabetes in the ileum, diminished. The Proteobacteria were
represented only by the genus Bordatella (order Burkholderiales). These changes in
the composition of microbiota may correlate with the glycaemic control and the
restoration of the enteric microenvironment, which prevented the neuronal cell
loss and the structural damage of the capillary wall. Insulin treatment rearranged
the microbiota of the ileum so that it became very distinct from both the control
and the diabetes populations. The microbiome of the ileum in insulin-treated
diabetes resembled the colon community and insulin could not restore the control
microbiota in either GI segment.
The relative abundance of the major phyla Bacteroidetes and Firmicutes, which
predominate in both the human and the murine colon [33, 49] did not indicate a
striking difference between the healthy and the diseased state or that in response
to insulin replacement in comparison with the ileum. In contrast, the alterations
in both the relative abundance and the composition of the phylum Proteobacteria
here were pronounced. The insulin treatment of the diabetic rats brought about
significant alterations in the colon microbiome, though the changes were less
marked relative to the control and the diabetic rats. The most noticeable of these
modifications was a general escalation of the diversity of the microbial community
in both the ileum and the colon. A proliferation of microbial diversity is a general
sign of a healthier environment in the human gut [22, 33]. Insulin replacement
was accompanied by a fundamental change within the phylum Proteobacteria in
the ileum and the colon. Their overall abundance decreased spectacularly and the
genus Klebsiella was eradicated. Roesch et al. [49] reported that strains belonging
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in the genera Lactobacillus and Bifidobacterium were more abundant in genetically
diabetes-resistant rats, which correlated well with the appearance of the order
Bifidobacteriales in insulin-treated animals in our case. Their abundance was 9%
and 7% in the insulin-treated ileum and colon, respectively. However, in mice a
pro-diabetogenic, gluten-containing diet increased the relative numbers of the
Bifidobacterium, the Barnesiella and the Tanerella [32].
Insulin appropriately controlled the hyperglycaemia in the colon and prevented
the myenteric neuronal loss. Unlike the ileum, the structural alterations of the
microvessels remained unchanged relative to the diabetic counterparts [11]. This
suggests that, although hyperglycaemia can be controlled by appropriate insulin
medication, some of the associated system irregularities persist. The fact that
insulin did not restore normal conditions in the capillary endothelium or in the
microbiota of the ileum or the colon further indicated that the main location of
hyperglycaemia-dependent events is in the ileum, and studies involving only the
colon or the stools are unlikely to give an overall picture.
Conclusions
The regionally distinct alterations in the microbiome along the GI tract of rats
with STZ-induced diabetes or insulin-treated diabetes correlated well with the
regional manifestations of the diabetes-related enteric neuropathy and mesenteric
capillary damage. This suggests that the myenteric neurones in a distinct gut
segment are not simply targets of T1D, but rather active participants in the
pathogenic pathways initiated by the regionally altered microbiota, a common
environmental trigger for autoimmune diabetes and enteric neuropathy. The
characteristic upsurge of the Gram-negative Klebsiella in the ileum could be
directly associated with the inflammation, which is a decisive element in the onset
of autoimmune diabetes. At the same time, the Klebsiella invasion could be a
critical environmental trigger, initiating the pathological cascade in the gut wall
and resulting in compromised neuro-immune interactions, enteric neuropathy
and harmful GI syndromes. As the Proteobacteria exhibited the most significant
changes seen in diabetes, we suggest that, rather than the predominant Firmicutes
and Bacteroidetes, the less abundant Proteobacteria should be at the focus of the
diagnosis and the potential therapy of T1D. More work is needed to establish
clearly whether the Klebsiella are the cause or a consequence of the autoimmune
disease. The massive invasion of the Klebsiella in the ileum and the related
myenteric neuropathy raise the possibility that the Klebsiella might be regarded as
a biomarker of the disease. The microbial diversity in both the ileum and the
colon increased enormously in response to insulin treatment. The multiplicity of
the bacteria was less profound in the colon, which might explain why the diabetes-
related structural alterations in the mesenteric capillaries here were only partially
restored in the insulin-treated diabetic rats. Although hyperglycaemia can be
controlled by appropriate insulin replacement, some of the associated irregula-
Microbiome along the Rat Gut in Type 1 Diabetes
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rities persist in the different intestinal segments and influence the outcome of the
therapies.
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